Metagenics Inc. launches new nutraceutical

March 10, 2009 — Metagenics Inc. announced it has launched a new nutraceutical called Ostera. This unique nutritional supplement supports the special needs of postmenopausal women, whose bone health may be affected by declining estrogen levels.

Ostera is formulated to target bone remodeling, the normal lifelong process whereby old or damaged bone tissue is replaced by new bone tissue. Conventional approaches to postmenopausal bone health may have adverse affects or not be well-tolerated. By contrast, Ostera is a gentle, all-natural formula without reported serious adverse effects. Ostera is intended to complement natural bone mineralization support products, such as calcium and other minerals.

Source: Metagenics Inc., www.metagenics.com